BIODEXA PHARMACEUTICALS PLC SPON ADS EACH REP 5 ORD(BDRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BDRX BIODEXA PHARMACEUTICALS PLC SPON ADS EACH REP 5 ORD

Not Yet Opened 05-09 16:00:00 EDT

0.9997

-0.0003

-0.03%

盘后0.9500

-0.0497-4.97%

19:59 EDT

High1.04	Low0.9800	Vol141.05K
Open1.04	D1 Closing1.00	Amplitude6.00%
Mkt Cap4.38M	Tradable Cap2.79M	Total Shares4.38M
T/O141.86K	T/O Rate5.05%	Tradable Shares2.79M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"BDRX","market":"US","secType":"STK","nameCN":"BIODEXA PHARMACEUTICALS PLC SPON ADS EACH REP 5 ORD","latestPrice":0.9997,"timestamp":1715284800000,"preClose":1,"halted":0,"volume":141053,"hourTrading":{"tag":"盘后","latestPrice":0.95,"preClose":0.9997,"latestTime":"19:59 EDT","volume":28899,"amount":27136.3499,"timestamp":1715299164678},"delay":0,"floatShares":2790700,"shares":4384996,"eps":-11.419252,"marketStatus":"Not Yet Opened","change":-0.0003,"latestTime":"05-09 16:00:00 EDT","open":1.04,"high":1.04,"low":0.98,"amount":141864.760015,"amplitude":0.06,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-11.419252,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1715328000000},"marketStatusCode":0,"adr":0,"adrRate":400,"listingDate":1449464400000,"exchange":"NASDAQ","adjPreClose":1,"preHourTrading":{"tag":"盘前","latestPrice":1.05,"preClose":1,"latestTime":"09:25 EDT","volume":4316,"amount":4365.1816831999995,"timestamp":1715261144399},"postHourTrading":{"tag":"盘后","latestPrice":0.95,"preClose":0.9997,"latestTime":"19:59 EDT","volume":28899,"amount":27136.3499,"timestamp":1715299164678},"volumeRatio":0.519093},"requestUrl":"/m/hq/s/BDRX/tweets","defaultTab":"tweets","newsList":[{"id":"2434094914","title":"Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With Devastating Precancerous Condition","url":"https://stock-news.laohu8.com/highlight/detail?id=2434094914","media":"ACCESSWIRE","top":-1,"share":"https://ttm.financial/m/news/2434094914?lang=en_us&edition=fundamental","pubTime":"2024-05-09 20:00","pubTimestamp":1715256000,"startTime":"0","endTime":"0","summary":"Registrational phase 3 clinical trials of Biodexa's  candidate eRapa are expected to start first quarter next year.The candidate was developed with private funds and acquired by Biodexa, its second portfolio expansion in less than six months, and is supported by a $17 million grant from the State of Texas.Biodexa Pharmaceuticals , an acquisition-focused biopharmaceutical company, recently acquired exclusive worldwide rights to eRapa, a phase 3-ready candidate for slowing or preventing the growth of aggressive FAP precancerous polyps in the GI tract.Although potentially suitable for several indications, including bladder and prostate cancers, eRapa is being initially developed for treating precancerous FAP, the polyps that presage cancer of the colon and/or rectum in approximately 100,000 individuals in the U.S. and Europe. FAP most typically results in surgical removal of the colon and/or rectum. The procedures rid the body of polyps that are on track to become cancerous and reduce the","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/NDI7kF0aB7C.iLbCu83Wxg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/2657cfc15d79f39cc08825ea473882bb","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/NDI7kF0aB7C.iLbCu83Wxg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/2657cfc15d79f39cc08825ea473882bb"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biodexa-looks-prevent-delay-worst-120000160.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432044304","title":"Biodexa’s eRapa Shows Promise for FAP Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2432044304","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2432044304?lang=en_us&edition=fundamental","pubTime":"2024-05-01 01:57","pubTimestamp":1714499832,"startTime":"0","endTime":"0","summary":"Biodexa Pharmaceuticals Plc (BDRX) has released an update. Biodexa Pharmaceuticals PLC announces that Emtora Biosciences will present results from ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biodexas-erapa-shows-promise-for-fap-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biodexas-erapa-shows-promise-for-fap-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2431932152","title":"Annovis Bio, Cyclacel Pharmaceuticals, Biodexa Pharmaceuticals among healthcare movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2431932152","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2431932152?lang=en_us&edition=fundamental","pubTime":"2024-04-30 22:01","pubTimestamp":1714485667,"startTime":"0","endTime":"0","summary":"Gainers: Cyclacel Pharmaceuticals  +35%. GeneDx Holdings  +31%. Eliem Therapeutics  +18%. JanOne  +13%. Harmony Biosciences Holdings  +15%.  Losers: NRX Pharmaceuticals  -26%. NewGenIvf Group  -12%. Annovis Bio  -12%. GE HealthCare Technologies  -9%. Biodexa Pharmaceuticals Plc ADR  -11%.   S&P 500 Health Care Sector +0.45% to 1643.55. Health Care Equipment & Services -0.37% to 1921.91. Pharmaceuticals, Biotechnology & Life Science which contributes 58% to index is +0.73% to 1334.8.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4096292-annovis-bio-cyclacel-pharmaceuticals-biodexa-pharmaceuticals-among-healthcare-movers","is_publish_highlight":false,"gpt_icon":0},{"id":"2431534144","title":"NIVF, BDRX and ZAPP among pre-market losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2431534144","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2431534144?lang=en_us&edition=fundamental","pubTime":"2024-04-30 20:24","pubTimestamp":1714479889,"startTime":"0","endTime":"0","summary":"Losers: Medifast  -20% after Q1 earnings release. Lichen China Ltd  -18%. Chegg  -15% after Q1 earnings release. Coursera  -14% after Q1 earnings release. Mesoblast Ltd  -10% provided activity report for Quarter ended March 31, 2024. NewGenIvf Group Ltd  -9%. GE HealthCare Technologies  -8% after Q1 earnings release.  Zapp Electric Vehicles Group Ltd  -7%. Microstrategy  -7% after Q1 earnings release. HWH International  -7%. Banco Bilbao Vizcaya Argentaria.  -6%. Biodexa Pharmaceuticals Plc  -5%. Yum China Holdings  -5% after Q1 earnings release. Annovis Bio  -5%.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4096173-nivf-bdrx-and-zapp-among-pre-market-losers","is_publish_highlight":false,"gpt_icon":1},{"id":"2431712323","title":"Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2431712323","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2431712323?lang=en_us&edition=fundamental","pubTime":"2024-04-30 15:52","pubTimestamp":1714463520,"startTime":"0","endTime":"0","summary":"April 30, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa in Familial Adenomatous Polyposis to be Presented a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/04/30/2872564/0/en/Biodexa-s-Licensor-Emtora-to-Announce-Phase-2-Clinical-Trial-Results-of-eRapa-in-Familial-Adenomatous-Polyposis-to-be-Presented-at-Prestigious-2024-Digestive-Disease-Week-Annual-Me.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431859408","title":"ALT, CYCC and DB among pre-market losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2431859408","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2431859408?lang=en_us&edition=fundamental","pubTime":"2024-04-29 20:17","pubTimestamp":1714393057,"startTime":"0","endTime":"0","summary":"Losers: Clever Leaves Holdings  -61% announces Voluntary Delisting and SEC Deregistration. Addex Therapeutics Ltd  -52% provides update on ADX71149 phase 2 Epilepsy study. Cyclacel Pharmaceuticals  -21%. Nature Wood Group Ltd  -15%. mF International Ltd  -14%. Biodexa Pharmaceuticals  -11%.  Avenue Therapeutics  -11% announces exercise of warrants for $4.4 Million in gross proceeds. reAlpha Tech Corp.  -10%. Nuzee  -9%. Deutsche Bank  -8%. Blue Hat Interactive Entertainment Technology  -8%. Lichen China Ltd  -7%. Altimmune  -6%. Hub Cyber Security Ltd  -5%. Daqo New Energy Corp  -5% after Q1 earnings release.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4095406-alt-cycc-and-db-among-pre-market-losers","is_publish_highlight":false,"gpt_icon":0},{"id":"2431061074","title":"12 ChatGPT Penny Stock Picks Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2431061074","media":"Insider Monkey","top":-1,"share":"https://ttm.financial/m/news/2431061074?lang=en_us&edition=fundamental","pubTime":"2024-04-29 00:01","pubTimestamp":1714320092,"startTime":"0","endTime":"0","summary":"In this article, we will take a detailed look atthe 12 ChatGPT Penny Stock Picks Right Now.For a quick overview of such stocks, read our article5ChatGPT Penny Stock Picks Right Now.In a world where inflation remains sticky, interest rates high and markets uncertain, why would anyone think of investing in individual stocks let alone riskier, volatile penny stocks?Akre Focused Fund, run by Akre Capital Management of legendary value investor Chuck Akre, shared some interesting insights in its Q1 letter to investors, highlighting how it was able to beat the market without relying on the Magnificent Seven stocks. The fund's commentary said that while the Mag. 7 companies of today have strong fundamentals and the stock market today isn’t anything like the la","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.YPaxkY3t1zu58QFHZgTcw--~B/aD02NjQ7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/8b76aed88991fbd1e16432eb3fa2041c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.YPaxkY3t1zu58QFHZgTcw--~B/aD02NjQ7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/8b76aed88991fbd1e16432eb3fa2041c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/12-chatgpt-penny-stock-picks-160132031.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430973541","title":"Sector Update: Health Care Stocks Edge Higher Late Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2430973541","media":"MT Newswires","top":-1,"share":"https://ttm.financial/m/news/2430973541?lang=en_us&edition=fundamental","pubTime":"2024-04-27 03:57","pubTimestamp":1714161434,"startTime":"0","endTime":"0","summary":"Health care stocks were advancing late Friday afternoon, with the NYSE Health Care Index adding 0.2% and the Health Care Select Sector SPDR Fund  up 0.1%.In corporate news, PTC Therapeutics  shares jumped 13%, a day after the company posted Q1 results topping consensus estimates.Pfizer  said Friday the US Food and Drug Administration has approved Beqvez to treat hemophilia B, a rare genetic bleeding disorder, in adult patients. Its shares added 0.8%.ResMed  shares surged 19% after the company reported fiscal Q3 non-GAAP earnings of $2.13 per diluted share, up from $1.68 a year earlier. Analysts surveyed by Capital IQ expected $1.91.Biodexa Pharmaceuticals  soared 73% after it said Friday it has signed a deal with Emtora Biosciences for the exclusive, global rights for eRapa, a phase 3-ready drug to treat familial adenomatous polyposis, an inherited disease that affects the gastrointestinal tract.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sector-health-care-stocks-edge-195714791.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430208191","title":"Biodexa Pharmaceuticals Seals Deal with Emtora Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2430208191","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2430208191?lang=en_us&edition=fundamental","pubTime":"2024-04-26 21:58","pubTimestamp":1714139933,"startTime":"0","endTime":"0","summary":"Biodexa Pharmaceuticals Plc (BDRX) has released an update. Biodexa Pharmaceuticals PLC has entered into an exclusive license and collaboration agre...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biodexa-pharmaceuticals-seals-deal-with-emtora-biosciences?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biodexa-pharmaceuticals-seals-deal-with-emtora-biosciences?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2430520899","title":"Biodexa shares rally 126% on rapamycin licensing deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2430520899","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2430520899?lang=en_us&edition=fundamental","pubTime":"2024-04-26 21:56","pubTimestamp":1714139793,"startTime":"0","endTime":"0","summary":"Shares of Biodexa (NASDAQ:BDRX) soared 126% in early trading Friday after the company announced it had entered into an exclusive worldwide license to develop and commercialize eRapa, also known as rap","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1195310802/image_1195310802.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1195310802/image_1195310802.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4094914-biodexa-shares-rally-on-rapamycin-licensing-deal","is_publish_highlight":false,"gpt_icon":1},{"id":"2430127608","title":"Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2430127608","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2430127608?lang=en_us&edition=fundamental","pubTime":"2024-04-26 20:30","pubTimestamp":1714134600,"startTime":"0","endTime":"0","summary":"Biodexa Enters Into Exclusive License to eRapa, a Phase 3 Ready Asset for theTreatment of Familial Adenomatous Polyposis . Worldwide rights come with $17 million in non-dilutive grant funding for Pivotal Phase 3 trial in FAP. An estimated 100,000 in U.S. and Europe are afflicted with FAP, precancerous polyps that typically lead to surgical removal of the colon and/or rectum. Stephen Dufilho, Executive Chairman of Emtora added, “The transaction with Biodexa is the culmination of a decade-long effort to advance our potentially game-changing eRapa to a registrational Phase 3 trial - and ultimately to patients in need. Our story began in San Antonio – where eRapa was originally invented at the University of Texas and funded in part by grants from the Cancer Prevention Research Institute of Texas. We thank the scientists, clinicians, investors and biotech executives that supported o","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/QrDcHMo0BO34lL4Yg91nkA--~B/aD02OTY7dz02OTY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/75c44019afb5b0486f0ecb261fc41c32","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/QrDcHMo0BO34lL4Yg91nkA--~B/aD02OTY7dz02OTY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/75c44019afb5b0486f0ecb261fc41c32"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biodexa-enters-exclusive-license-erapa-123000458.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428264554","title":"Navigating Uncertainty: Biodexa Pharmaceuticals and the Impact of Geopolitical Turmoil on Pharma’s Bottom Line","url":"https://stock-news.laohu8.com/highlight/detail?id=2428264554","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2428264554?lang=en_us&edition=fundamental","pubTime":"2024-04-20 14:01","pubTimestamp":1713592864,"startTime":"0","endTime":"0","summary":"Biodexa Pharmaceuticals Plc (BDRX) has disclosed a new risk, in the Capital Markets category. Biodexa Pharmaceuticals Plc faces significant busines...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/navigating-uncertainty-biodexa-pharmaceuticals-and-the-impact-of-geopolitical-turmoil-on-pharmas-bottom-line?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/navigating-uncertainty-biodexa-pharmaceuticals-and-the-impact-of-geopolitical-turmoil-on-pharmas-bottom-line?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2428694535","title":"Biodexa Pharmaceuticals reports Preliminary FY results","url":"https://stock-news.laohu8.com/highlight/detail?id=2428694535","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2428694535?lang=en_us&edition=fundamental","pubTime":"2024-04-20 05:23","pubTimestamp":1713561797,"startTime":"0","endTime":"0","summary":"Biodexa Pharmaceuticals press release  : FYBiodexa generated consolidated total gross revenue of 0.38m. Net cash outflow from operating activities in 2023 was 6.83m  driven by a net loss of 7.08  and after negative movements in working capital of 0.05m. More on Biodexa Pharmaceuticals  Biodexa stock slides 7% amid data for two drug studies Biodexa stock jumps on allowance of U.S. patent covering Tolimidone Seeking Alpha’s Quant Rating on Biodexa Pharmaceuticals Historical earnings data for Biodexa Pharmaceuticals Financial information for Biodexa Pharmaceuticals","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4091679-biodexa-pharmaceuticals-reports-preliminary-fy-results","is_publish_highlight":false,"gpt_icon":0},{"id":"2428676654","title":"Biodexa Pharmaceuticals Reports 2023 Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2428676654","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2428676654?lang=en_us&edition=fundamental","pubTime":"2024-04-19 21:27","pubTimestamp":1713533257,"startTime":"0","endTime":"0","summary":"Biodexa Pharmaceuticals Plc (BDRX) has released an update. Biodexa Pharmaceuticals PLC, a NASDAQ-listed biotech firm specializing in innovative can...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biodexa-pharmaceuticals-reports-2023-milestones?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biodexa-pharmaceuticals-reports-2023-milestones?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2428365390","title":"Preliminary Results for the Year Ended 31 December 2023","url":"https://stock-news.laohu8.com/highlight/detail?id=2428365390","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2428365390?lang=en_us&edition=fundamental","pubTime":"2024-04-19 12:00","pubTimestamp":1713499200,"startTime":"0","endTime":"0","summary":"19 April 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2023 Biodexa Pharmaceuticals PL","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/04/19/2866120/0/en/Preliminary-Results-for-the-Year-Ended-31-December-2023.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2424144910","title":"HUT, CXAI and BDRX among pre-market losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2424144910","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2424144910?lang=en_us&edition=fundamental","pubTime":"2024-04-02 20:37","pubTimestamp":1712061477,"startTime":"0","endTime":"0","summary":"Losers: Acorda Therapeutics (ACOR) -76% as it files for Chapter 11 bankruptcy. Gritstone Bio (GRTS) -43% on prices $32.5M equity offering. Verve Therapeutics (VERV) -36% after pausing trial enrollment","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4086212-hut-cxai-and-bdrx-among-pre-market-losers","is_publish_highlight":false,"gpt_icon":0},{"id":"2424719504","title":"MSTR, BIOR and ARBK among pre-market losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2424719504","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2424719504?lang=en_us&edition=fundamental","pubTime":"2024-04-01 20:31","pubTimestamp":1711974675,"startTime":"0","endTime":"0","summary":"Losers: Mountain Crest Acquisition Corp IV  -60%. Fractyl Health  -22% reports fourth quarter and full year 2023 financial results. Avalo Therapeutics  -16% after FY earnings release. Biora Therapeutics  -14% announces $6 Million registered direct offering priced at-the-market under Nasdaq rules.  Biodexa Pharmaceuticals Plc  -12%. Cleanspark  -10% bitcoin production jumps 24% M/M in March. Inspira Technologies Oxy B.H.N. Ltd  -9% on $1.65M direct funding. Griid Infrastructure  -8%. Cazoo Group Ltd  -10%. Kidpik Corp  -7%. Argo Blockchain Plc  -6%. Microstrategy  -6%. Aditxt  -5%. Ocean Biomedical  -5%. System1  -5%. Lixte Biotechnology Holdings  -5%.   More on Pre-market losers & stocks.  MicroStrategy Is A $1 Box Of Bitcoin Trading For $1.91 Biora Therapeutics, Inc.  Q4 2023 Earnings Call Transcript MicroStrategy: A Bad Deal For Investors MicroStrategy among most squeezable as crypto short interest climbs Is MicroStrategy, the bitcoin trade, better than Bitcoin?","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4085528-mstr-bior-and-arbk-among-pre-market-losers","is_publish_highlight":false,"gpt_icon":0},{"id":"2423117745","title":"Gold Gains 1%; Walgreens Narrows Earnings Forecast","url":"https://stock-news.laohu8.com/highlight/detail?id=2423117745","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2423117745?lang=en_us&edition=fundamental","pubTime":"2024-03-29 00:30","pubTimestamp":1711643408,"startTime":"0","endTime":"0","summary":"U.S. stocks traded slightly higher midway through trading, with the S&amp;P 500 gaining around 0.1% on Thursday.\n\nThe Dow traded up 0.06% to 39,785.87 while the NASDAQ rose 0.06% to 16,408.04. The S&amp;P 500 also rose, gaining, 0.13% to 5,255.09.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/03/37987963/gold-gains-1-walgreens-narrows-earnings-forecast","is_publish_highlight":false,"gpt_icon":0},{"id":"2422160948","title":"Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2422160948","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2422160948?lang=en_us&edition=fundamental","pubTime":"2024-03-28 20:18","pubTimestamp":1711628280,"startTime":"0","endTime":"0","summary":"Topline Results For Progression-Free Survival Expected In Q2 2024CARDIFF, UK / ACCESSWIRE / March 28, 2024 / Biodexa Pharmaceuticals (NASDAQ: BDRX) (\"Biodexa\"), an acquisition-focused biopharmaceutica","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=22991578","is_publish_highlight":false,"gpt_icon":0},{"id":"2420235506","title":"BRIEF-Biodexa Pharmaceuticals Files For Offering Of Up To 1.3 Mln Ordinary Shares By The Selling Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2420235506","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2420235506?lang=en_us&edition=fundamental","pubTime":"2024-03-19 05:11","pubTimestamp":1710796266,"startTime":"0","endTime":"0","summary":"March 18 (Reuters) - Biodexa Pharmaceuticals PLC :   * BIODEXA PHARMACEUTICALS PLC FILES FOR OFFERING OF UP TO 1.3 MILLION ORDINARY SHARES BY THE SELLING SHAREHOLDERS - SEC FILINGSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.midatechpharma.com","stockEarnings":[{"period":"1week","weight":-0.1938},{"period":"1month","weight":0.0098},{"period":"3month","weight":-0.2369},{"period":"6month","weight":-0.5903},{"period":"1year","weight":-0.9489},{"period":"ytd","weight":-0.627}],"compareEarnings":[{"period":"1week","weight":0.03},{"period":"1month","weight":0.0016},{"period":"3month","weight":0.0378},{"period":"6month","weight":0.1806},{"period":"1year","weight":0.2599},{"period":"ytd","weight":0.0944}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom. The company is developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. In addition, the company offers licensing for MTD 201 (Q-octreotide) and MTD211 (Q-brexpiprazole). The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":-0.041942},{"month":2,"riseRate":0.222222,"avgChangeRate":0.297959},{"month":3,"riseRate":0.111111,"avgChangeRate":-0.193799},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.06748},{"month":5,"riseRate":0.111111,"avgChangeRate":-0.220881},{"month":6,"riseRate":0.25,"avgChangeRate":-0.067298},{"month":7,"riseRate":0.5,"avgChangeRate":0.071796},{"month":8,"riseRate":0.625,"avgChangeRate":0.154367},{"month":9,"riseRate":0,"avgChangeRate":-0.253452},{"month":10,"riseRate":0.125,"avgChangeRate":-0.120617},{"month":11,"riseRate":0.125,"avgChangeRate":-0.140804},{"month":12,"riseRate":0.25,"avgChangeRate":-0.199965}],"exchange":"NASDAQ","name":"BIODEXA PHARMACEUTICALS PLC SPON ADS EACH REP 5 ORD","nameEN":"BIODEXA PHARMACEUTICALS PLC SPON ADS EACH REP 5 ORD"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BIODEXA PHARMACEUTICALS PLC SPON ADS EACH REP 5 ORD(BDRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BIODEXA PHARMACEUTICALS PLC SPON ADS EACH REP 5 ORD(BDRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BIODEXA PHARMACEUTICALS PLC SPON ADS EACH REP 5 ORD,BDRX,BIODEXA PHARMACEUTICALS PLC SPON ADS EACH REP 5 ORD股票,BIODEXA PHARMACEUTICALS PLC SPON ADS EACH REP 5 ORD股票老虎,BIODEXA PHARMACEUTICALS PLC SPON ADS EACH REP 5 ORD股票老虎国际,BIODEXA PHARMACEUTICALS PLC SPON ADS EACH REP 5 ORD行情,BIODEXA PHARMACEUTICALS PLC SPON ADS EACH REP 5 ORD股票行情,BIODEXA PHARMACEUTICALS PLC SPON ADS EACH REP 5 ORD股价,BIODEXA PHARMACEUTICALS PLC SPON ADS EACH REP 5 ORD股市,BIODEXA PHARMACEUTICALS PLC SPON ADS EACH REP 5 ORD股票价格,BIODEXA PHARMACEUTICALS PLC SPON ADS EACH REP 5 ORD股票交易,BIODEXA PHARMACEUTICALS PLC SPON ADS EACH REP 5 ORD股票购买,BIODEXA PHARMACEUTICALS PLC SPON ADS EACH REP 5 ORD股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BIODEXA PHARMACEUTICALS PLC SPON ADS EACH REP 5 ORD(BDRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BIODEXA PHARMACEUTICALS PLC SPON ADS EACH REP 5 ORD(BDRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction